Mebeverine - Isotope Labelled Standards
References
FAQ's
References
- V. Philips' Gloeilampenfabrieken, Improvements in or relating to the production of esterified amino-alcohols, GB1009082A, November 3, 1965
- De Schutter, J. A.; De Croo, F.; Van der Weken, G.; Van den Bossche, W.; De Moerloose, P., Stability study and quantitative determination of mebeverine hydrochloride in tablets by means of reversed-phase high-performance liquid chromatography, Chromatographia, Volume: 20, Issue: 3, Pages: 185-92, 1985
Frequently Asked Questions
Can Mebeverine impurities affect the bioavailability of the active ingredient?
Some impurities in Mebeverine formulations can potentially impact the bioavailability of the active ingredient, leading to variations in drug absorption and effectiveness.
Are Mebeverine impurities tested for their potential interactions with other drugs?
Impurities in Mebeverine are not tested for specific interactions with other drugs. However, drug-drug interactions involving the active ingredient are considered based on clinical knowledge.
Can Mebeverine impurities be present in different polymorphic forms?
Impurities in Mebeverine can exist in different polymorphic forms, influencing their physicochemical properties and potential impact on product quality.
What is the recommended storage temperature for Mebeverine impurities?
Mebeverine impurities should be stored, at a controlled room temperature, usually between 2-8 °C.
Note: Products protected by valid patents by a manufacturer are not offered for sale in countries having patent protection. The sale of such products constitutes a patent infringement, and its liability is at the buyer's risk.